Dragon pharma
- Thread starter piskoton
- Start date
I'm gonna punch your parents in the face for raising a fucking idiot.
rofl. Yes!
![[9oNe6]BillyD@kid](/forums/data/avatars/m/2/2076.jpg?1477587594){kind=avatar}
Fuck, I woke up and this the first thread I read... Lol, hahaha thanks for the wake up laugh 44 !
Dragon Pharma:
Founded: Sepetember 1998
Listed: TSX: DDD and OTC BB
Shares Outstanding: 20,331,000
Head Office: Vancouver, Canada
Manufacturing Facility: Nanjing, China
Number of employees: 160
Sales Revenue: US$3.1 million
Approved Product: Erythropoietin(EPO) for use in patients with renal failure
Product in Development: Slow-Release EPO, GTCSF, Human Lusulin, TPO
Clinical Trials in Progress:
Clinical trials & market approval submission for EPO in surgery patients
Pivotal Phase II/III studies for EPO in cancer patients to be completed during 2002
PROVED TECHNOLOGY PLATFORM
Developed high-yield EPO cell line based on proprietary DNA vector technology platform
Established bioreactor-based, commercial scale production of EPO
ESTABLISHED COMMERCIAL PRODUCTION OF EPO
Acquired and upgraded production facility
Awarded Good Manufacturing Practices (GMP) certification
Produced 3.3 million doses (2000 IU equivalents) in 2001
CAPTURED 30% OF EPO MARKET SHARE IN CHINA
Expanded distribution network to 75% of kidney dialysis facilities
Endorsed by Chinese Medical Association for superior quality EPO
EXPANDED EPO SALES INTERNATIONALLY
Signed 11 licensing agreements covering 90 developing world countries
Filed international regulatory submissions
Received marketing approvals and initiated sales in Egypt, India, and Peru
DEVELOPED ADDITONAL APPLICATIONS FOR EPO
Completed pivotal Phase II/III clinical trial and submitted SDA application for use of EPO in surgery-related anemia
Initiated pivotal Phase II/III clinical trial for use of EPO in anemia related to chemotherapy
ACQUIRED 4-PRODUCT PIPELINE
Acquired ownership of TPO, G-CSF and Human Insulin projects
Acquired exclusive worldwide manufacturing and Asian marketing rights to Slow-Release EPO
GENERATED SALES REVENUES
Generated revenues from EPO sales to China and international markets totaling $7.24 million
ATTRACTED SIGNIFICANT FINANCING
Raised $25 million in private placement financings
OBTAINED LISTING ON TSX
Listed on Toronto Stock Exchange (TSX) on May 9, 2002
Founded: Sepetember 1998
Listed: TSX: DDD and OTC BB
Shares Outstanding: 20,331,000
Head Office: Vancouver, Canada
Manufacturing Facility: Nanjing, China
Number of employees: 160
Sales Revenue: US$3.1 million
Approved Product: Erythropoietin(EPO) for use in patients with renal failure
Product in Development: Slow-Release EPO, GTCSF, Human Lusulin, TPO
Clinical Trials in Progress:
Clinical trials & market approval submission for EPO in surgery patients
Pivotal Phase II/III studies for EPO in cancer patients to be completed during 2002
PROVED TECHNOLOGY PLATFORM
Developed high-yield EPO cell line based on proprietary DNA vector technology platform
Established bioreactor-based, commercial scale production of EPO
ESTABLISHED COMMERCIAL PRODUCTION OF EPO
Acquired and upgraded production facility
Awarded Good Manufacturing Practices (GMP) certification
Produced 3.3 million doses (2000 IU equivalents) in 2001
CAPTURED 30% OF EPO MARKET SHARE IN CHINA
Expanded distribution network to 75% of kidney dialysis facilities
Endorsed by Chinese Medical Association for superior quality EPO
EXPANDED EPO SALES INTERNATIONALLY
Signed 11 licensing agreements covering 90 developing world countries
Filed international regulatory submissions
Received marketing approvals and initiated sales in Egypt, India, and Peru
DEVELOPED ADDITONAL APPLICATIONS FOR EPO
Completed pivotal Phase II/III clinical trial and submitted SDA application for use of EPO in surgery-related anemia
Initiated pivotal Phase II/III clinical trial for use of EPO in anemia related to chemotherapy
ACQUIRED 4-PRODUCT PIPELINE
Acquired ownership of TPO, G-CSF and Human Insulin projects
Acquired exclusive worldwide manufacturing and Asian marketing rights to Slow-Release EPO
GENERATED SALES REVENUES
Generated revenues from EPO sales to China and international markets totaling $7.24 million
ATTRACTED SIGNIFICANT FINANCING
Raised $25 million in private placement financings
OBTAINED LISTING ON TSX
Listed on Toronto Stock Exchange (TSX) on May 9, 2002
Similar threads
